nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—SLC6A3—attention deficit hyperactivity disorder	0.467	0.572	CbGaD
Citalopram—SLC6A4—attention deficit hyperactivity disorder	0.349	0.428	CbGaD
Citalopram—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.00999	0.186	CbGeAlD
Citalopram—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00531	0.0986	CbGeAlD
Citalopram—Escitalopram—SLC6A3—attention deficit hyperactivity disorder	0.00448	0.572	CrCbGaD
Citalopram—Escitalopram—SLC6A4—attention deficit hyperactivity disorder	0.00335	0.428	CrCbGaD
Citalopram—SLC6A3—forebrain—attention deficit hyperactivity disorder	0.00153	0.0285	CbGeAlD
Citalopram—HTR2C—forebrain—attention deficit hyperactivity disorder	0.00148	0.0275	CbGeAlD
Citalopram—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.0014	0.0261	CbGeAlD
Citalopram—CHRM1—forebrain—attention deficit hyperactivity disorder	0.0014	0.026	CbGeAlD
Citalopram—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.00124	0.023	CbGeAlD
Citalopram—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.00118	0.022	CbGeAlD
Citalopram—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.00115	0.0214	CbGeAlD
Citalopram—SLC6A3—midbrain—attention deficit hyperactivity disorder	0.00101	0.0188	CbGeAlD
Citalopram—HTR2C—midbrain—attention deficit hyperactivity disorder	0.000979	0.0182	CbGeAlD
Citalopram—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000972	0.0181	CbGeAlD
Citalopram—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.000928	0.0172	CbGeAlD
Citalopram—HRH1—forebrain—attention deficit hyperactivity disorder	0.00089	0.0165	CbGeAlD
Citalopram—SLC6A3—nervous system—attention deficit hyperactivity disorder	0.000832	0.0155	CbGeAlD
Citalopram—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000805	0.015	CbGeAlD
Citalopram—SLC6A3—central nervous system—attention deficit hyperactivity disorder	0.000801	0.0149	CbGeAlD
Citalopram—SLC6A3—cerebellum—attention deficit hyperactivity disorder	0.000783	0.0146	CbGeAlD
Citalopram—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.000775	0.0144	CbGeAlD
Citalopram—CYP2B6—cardiovascular system—attention deficit hyperactivity disorder	0.000771	0.0143	CbGeAlD
Citalopram—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.000763	0.0142	CbGeAlD
Citalopram—CHRM1—nervous system—attention deficit hyperactivity disorder	0.00076	0.0141	CbGeAlD
Citalopram—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.000734	0.0136	CbGeAlD
Citalopram—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.000732	0.0136	CbGeAlD
Citalopram—CYP2E1—cardiovascular system—attention deficit hyperactivity disorder	0.000723	0.0134	CbGeAlD
Citalopram—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000677	0.0126	CbGeAlD
Citalopram—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.000672	0.0125	CbGeAlD
Citalopram—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.000647	0.012	CbGeAlD
Citalopram—SLC6A3—brain—attention deficit hyperactivity disorder	0.000636	0.0118	CbGeAlD
Citalopram—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000624	0.0116	CbGeAlD
Citalopram—HTR2C—brain—attention deficit hyperactivity disorder	0.000615	0.0114	CbGeAlD
Citalopram—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000601	0.0112	CbGeAlD
Citalopram—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000587	0.0109	CbGeAlD
Citalopram—SLC6A4—brain—attention deficit hyperactivity disorder	0.000583	0.0108	CbGeAlD
Citalopram—CHRM1—brain—attention deficit hyperactivity disorder	0.000581	0.0108	CbGeAlD
Citalopram—SLC6A2—brain—attention deficit hyperactivity disorder	0.000513	0.00954	CbGeAlD
Citalopram—CYP2B6—nervous system—attention deficit hyperactivity disorder	0.000495	0.0092	CbGeAlD
Citalopram—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000487	0.00905	CbGeAlD
Citalopram—HRH1—nervous system—attention deficit hyperactivity disorder	0.000483	0.00898	CbGeAlD
Citalopram—ADRA1A—brain—attention deficit hyperactivity disorder	0.000477	0.00887	CbGeAlD
Citalopram—CYP2B6—central nervous system—attention deficit hyperactivity disorder	0.000476	0.00885	CbGeAlD
Citalopram—HRH1—central nervous system—attention deficit hyperactivity disorder	0.000465	0.00865	CbGeAlD
Citalopram—CYP2E1—nervous system—attention deficit hyperactivity disorder	0.000464	0.00863	CbGeAlD
Citalopram—CYP2E1—central nervous system—attention deficit hyperactivity disorder	0.000447	0.00831	CbGeAlD
Citalopram—CYP2E1—cerebellum—attention deficit hyperactivity disorder	0.000437	0.00812	CbGeAlD
Citalopram—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000412	0.00766	CbGeAlD
Citalopram—CYP2B6—brain—attention deficit hyperactivity disorder	0.000378	0.00703	CbGeAlD
Citalopram—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000374	0.00694	CbGeAlD
Citalopram—HRH1—brain—attention deficit hyperactivity disorder	0.000369	0.00686	CbGeAlD
Citalopram—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000368	0.00683	CbGeAlD
Citalopram—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00036	0.00669	CbGeAlD
Citalopram—CYP2E1—brain—attention deficit hyperactivity disorder	0.000355	0.0066	CbGeAlD
Citalopram—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000354	0.00658	CbGeAlD
Citalopram—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000346	0.00643	CbGeAlD
Citalopram—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000322	0.00598	CbGeAlD
Citalopram—CYP2D6—brain—attention deficit hyperactivity disorder	0.000281	0.00522	CbGeAlD
Citalopram—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000264	0.00492	CbGeAlD
Citalopram—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000255	0.00473	CbGeAlD
Citalopram—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000249	0.00463	CbGeAlD
Citalopram—ABCB1—brain—attention deficit hyperactivity disorder	0.000202	0.00376	CbGeAlD
Citalopram—HRH1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.4e-05	0.000603	CbGpPWpGaD
Citalopram—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	7.4e-05	0.000602	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.38e-05	0.000601	CbGpPWpGaD
Citalopram—SLC6A4—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	7.32e-05	0.000596	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.3e-05	0.000595	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.26e-05	0.000591	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.25e-05	0.00059	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.23e-05	0.000588	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.23e-05	0.000588	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.2e-05	0.000586	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	7.2e-05	0.000586	CbGpPWpGaD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	7.2e-05	0.000586	CbGpPWpGaD
Citalopram—SLC6A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	7.14e-05	0.000581	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.11e-05	0.000579	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.09e-05	0.000577	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	7e-05	0.00057	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	6.98e-05	0.000568	CbGpPWpGaD
Citalopram—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	6.9e-05	0.000562	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	6.88e-05	0.00056	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	6.87e-05	0.000559	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	6.86e-05	0.000558	CbGpPWpGaD
Citalopram—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	6.85e-05	0.000558	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.83e-05	0.000556	CbGpPWpGaD
Citalopram—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	6.8e-05	0.000554	CbGpPWpGaD
Citalopram—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	6.79e-05	0.000553	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	6.79e-05	0.000553	CbGpPWpGaD
Citalopram—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	6.77e-05	0.000551	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	6.77e-05	0.000551	CbGpPWpGaD
Citalopram—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	6.75e-05	0.00055	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	6.75e-05	0.00055	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.72e-05	0.000547	CbGpPWpGaD
Citalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.72e-05	0.000547	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.7e-05	0.000545	CbGpPWpGaD
Citalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	6.67e-05	0.000543	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	6.67e-05	0.000543	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.59e-05	0.000537	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.58e-05	0.000536	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.56e-05	0.000534	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.46e-05	0.000526	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	6.45e-05	0.000525	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.33e-05	0.000515	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.31e-05	0.000514	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.21e-05	0.000506	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.92e-05	0.000482	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.9e-05	0.00048	CbGpPWpGaD
Citalopram—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	5.84e-05	0.000476	CbGpPWpGaD
Citalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.82e-05	0.000474	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.81e-05	0.000473	CbGpPWpGaD
Citalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.8e-05	0.000472	CbGpPWpGaD
Citalopram—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	5.8e-05	0.000472	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.8e-05	0.000472	CbGpPWpGaD
Citalopram—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	5.76e-05	0.000469	CbGpPWpGaD
Citalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.71e-05	0.000465	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.33e-05	0.000434	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.27e-05	0.000429	CbGpPWpGaD
Citalopram—HTR2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.12e-05	0.000417	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.07e-05	0.000413	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.02e-05	0.000409	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.01e-05	0.000408	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.93e-05	0.000402	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.71e-05	0.000384	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.62e-05	0.000376	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.61e-05	0.000375	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.6e-05	0.000375	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.58e-05	0.000373	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.56e-05	0.000372	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.56e-05	0.000372	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.55e-05	0.00037	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.53e-05	0.000369	CbGpPWpGaD
Citalopram—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	4.51e-05	0.000367	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.49e-05	0.000365	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.49e-05	0.000365	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.48e-05	0.000365	CbGpPWpGaD
Citalopram—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	4.48e-05	0.000365	CbGpPWpGaD
Citalopram—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	4.45e-05	0.000362	CbGpPWpGaD
Citalopram—HRH1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.43e-05	0.000361	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.43e-05	0.000361	CbGpPWpGaD
Citalopram—CHRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.42e-05	0.00036	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.4e-05	0.000358	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.39e-05	0.000358	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	4.38e-05	0.000357	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.38e-05	0.000357	CbGpPWpGaD
Citalopram—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.35e-05	0.000354	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.31e-05	0.000351	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.28e-05	0.000348	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.14e-05	0.000337	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.13e-05	0.000336	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.08e-05	0.000332	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.07e-05	0.000332	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.07e-05	0.000331	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.06e-05	0.00033	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.02e-05	0.000328	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.01e-05	0.000326	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.99e-05	0.000325	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.98e-05	0.000324	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.97e-05	0.000324	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.97e-05	0.000323	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.96e-05	0.000322	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.95e-05	0.000322	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.94e-05	0.000321	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.91e-05	0.000319	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.9e-05	0.000317	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.89e-05	0.000317	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.89e-05	0.000317	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.88e-05	0.000316	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.88e-05	0.000316	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.87e-05	0.000316	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.84e-05	0.000313	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.83e-05	0.000312	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.82e-05	0.000311	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.81e-05	0.000311	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.81e-05	0.000311	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.8e-05	0.00031	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.77e-05	0.000307	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.75e-05	0.000305	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.74e-05	0.000305	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.71e-05	0.000302	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.7e-05	0.000301	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.64e-05	0.000296	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.59e-05	0.000292	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.58e-05	0.000291	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.58e-05	0.000291	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.56e-05	0.00029	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.53e-05	0.000287	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.52e-05	0.000287	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.52e-05	0.000287	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.51e-05	0.000286	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.49e-05	0.000284	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.47e-05	0.000283	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.46e-05	0.000282	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.42e-05	0.000279	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.25e-05	0.000264	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.24e-05	0.000264	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.19e-05	0.00026	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	3.14e-05	0.000256	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.11e-05	0.000253	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.07e-05	0.00025	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.99e-05	0.000244	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.89e-05	0.000235	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	2.89e-05	0.000235	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.82e-05	0.00023	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—TPH2—attention deficit hyperactivity disorder	2.8e-05	0.000228	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.8e-05	0.000228	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—DPYD—attention deficit hyperactivity disorder	2.76e-05	0.000224	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—TPH2—attention deficit hyperactivity disorder	2.74e-05	0.000223	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.74e-05	0.000223	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.72e-05	0.000221	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—DPYD—attention deficit hyperactivity disorder	2.7e-05	0.00022	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.7e-05	0.000219	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.69e-05	0.000219	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.65e-05	0.000215	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.62e-05	0.000214	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.56e-05	0.000209	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.53e-05	0.000206	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.51e-05	0.000204	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.5e-05	0.000204	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.5e-05	0.000203	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.46e-05	0.0002	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.45e-05	0.000199	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.41e-05	0.000196	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.39e-05	0.000195	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.38e-05	0.000194	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.36e-05	0.000192	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.35e-05	0.000191	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.31e-05	0.000188	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.27e-05	0.000185	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.27e-05	0.000185	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.24e-05	0.000182	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.23e-05	0.000182	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.21e-05	0.00018	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.19e-05	0.000179	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.19e-05	0.000178	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.18e-05	0.000178	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.15e-05	0.000175	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.13e-05	0.000174	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.12e-05	0.000173	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	2.12e-05	0.000172	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.12e-05	0.000172	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.11e-05	0.000172	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.09e-05	0.00017	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.09e-05	0.00017	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	2.08e-05	0.00017	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.08e-05	0.00017	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.08e-05	0.000169	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	2.07e-05	0.000168	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.07e-05	0.000168	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.06e-05	0.000168	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.05e-05	0.000167	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.05e-05	0.000167	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	2.03e-05	0.000166	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.02e-05	0.000165	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	1.95e-05	0.000159	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.95e-05	0.000159	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.94e-05	0.000158	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.92e-05	0.000156	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	1.92e-05	0.000156	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.91e-05	0.000156	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.89e-05	0.000154	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.88e-05	0.000153	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.84e-05	0.00015	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.78e-05	0.000145	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—COMT—attention deficit hyperactivity disorder	1.7e-05	0.000138	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.69e-05	0.000138	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.68e-05	0.000137	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—COMT—attention deficit hyperactivity disorder	1.66e-05	0.000135	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.65e-05	0.000134	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.65e-05	0.000134	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	1.65e-05	0.000134	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.65e-05	0.000134	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	1.62e-05	0.000132	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.61e-05	0.000131	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.57e-05	0.000128	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.56e-05	0.000127	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.55e-05	0.000126	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.51e-05	0.000123	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.48e-05	0.000121	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.34e-05	0.000109	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.34e-05	0.000109	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.32e-05	0.000107	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.32e-05	0.000107	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	1.28e-05	0.000104	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	1.27e-05	0.000104	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	1.27e-05	0.000104	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.27e-05	0.000104	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.26e-05	0.000102	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	1.25e-05	0.000102	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	1.25e-05	0.000102	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.24e-05	0.000101	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.23e-05	0.000101	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	1.18e-05	9.6e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.17e-05	9.54e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.16e-05	9.48e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.02e-05	8.29e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	9.99e-06	8.14e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	9.92e-06	8.08e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.69e-06	7.89e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	9.62e-06	7.83e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.22e-06	6.69e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	7.71e-06	6.28e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	7.66e-06	6.24e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—EP300—attention deficit hyperactivity disorder	7.28e-06	5.93e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—EP300—attention deficit hyperactivity disorder	7.13e-06	5.8e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.12e-06	5.8e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.1e-06	5.78e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.99e-06	5.69e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	5.5e-06	4.48e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	5.37e-06	4.37e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	5.06e-06	4.12e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	4.28e-06	3.49e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	3.31e-06	2.69e-05	CbGpPWpGaD
